303 related articles for article (PubMed ID: 27645247)
1. Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.
Te Brake LH; van den Heuvel JJ; Buaben AO; van Crevel R; Bilos A; Russel FG; Aarnoutse RE; Koenderink JB
Antimicrob Agents Chemother; 2016 Dec; 60(12):7105-7114. PubMed ID: 27645247
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family.
Parvez MM; Kaisar N; Shin HJ; Jung JA; Shin JG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6558-6567. PubMed ID: 27550354
[TBL] [Abstract][Full Text] [Related]
3. Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates.
van der Velden M; Bilos A; van den Heuvel JJMW; Rijpma SR; Hurkmans EGE; Sauerwein RW; Russel FGM; Koenderink JB
Malar J; 2017 Oct; 16(1):422. PubMed ID: 29061131
[TBL] [Abstract][Full Text] [Related]
4. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
5. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine.
Elsby R; Chidlaw S; Outteridge S; Pickering S; Radcliffe A; Sullivan R; Jones H; Butler P
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971610
[TBL] [Abstract][Full Text] [Related]
7. Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
Shen H; Yao M; Sinz M; Marathe P; Rodrigues AD; Zhu M
Mol Pharm; 2019 Sep; 16(9):4065-4076. PubMed ID: 31335150
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.
Morrissey KM; Stocker SL; Chen EC; Castro RA; Brett CM; Giacomini KM
Clin Pharmacokinet; 2016 Apr; 55(4):495-506. PubMed ID: 26507723
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
[TBL] [Abstract][Full Text] [Related]
10. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
Li Q; Guo D; Dong Z; Zhang W; Zhang L; Huang SM; Polli JE; Shu Y
Toxicol Appl Pharmacol; 2013 Nov; 273(1):100-9. PubMed ID: 24001450
[TBL] [Abstract][Full Text] [Related]
12. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
13. Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.
Blanc Mettral J; Faller N; Cruchon S; Sottas L; Buclin T; Schild L; Choong E; Nahimana A; Decosterd LA
Drug Metab Lett; 2019; 13(2):102-110. PubMed ID: 30734690
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of
Parvez MM; Shin HJ; Jung JA; Shin JG
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223391
[No Abstract] [Full Text] [Related]
15. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
[TBL] [Abstract][Full Text] [Related]
16. A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker.
Luo L; Ramanathan R; Horlbogen L; Mathialagan S; Costales C; Vourvahis M; Holliman CL; Rodrigues AD
Anal Chem; 2020 Jul; 92(14):9745-9754. PubMed ID: 32551505
[TBL] [Abstract][Full Text] [Related]
17. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
Müller F; Weitz D; Mertsch K; König J; Fromm MF
Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
[TBL] [Abstract][Full Text] [Related]
18. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.
Minematsu T; Giacomini KM
Mol Cancer Ther; 2011 Mar; 10(3):531-9. PubMed ID: 21252289
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
[TBL] [Abstract][Full Text] [Related]
20. Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.
Pan X; Wang L; Gründemann D; Sweet DH
Antimicrob Agents Chemother; 2013 Oct; 57(10):5053-9. PubMed ID: 23917312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
